Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 26th at 6:00 PM EST.

To Purchase # 8922SC

8922SC 10 µg (With Carrier)
8922SF 10 µg (Carrier Free)
8922LC 50 µg (With Carrier)
8922LF 50 µg (Carrier Free)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human GM-CSF (hGM-CSF) Ala18 - Glu144 (Accession # NM_000758) was produced in E. coli at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hGM-CSF. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hGM-CSF does not have a Met on the amino terminus and has a calculated MW of 14477. DTT-reduced protein migrates as a 14 kDa polypeptide and non-reduced protein has slightly greater mobility due to intramolecular cystines. The expected amino-terminal APARS of recombinant hGM-CSF was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hGM-CSF was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 5-30 pg/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1μg hGM-CSF.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hGM-CSF. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

GM-CSF is produced by activated T cells, NK cells and macrophages (1,5). Target cells include granulocyte, monocyte precursors and subsets of differentiated myeloid cells (1,2,3). Many target cells require GM-CSF for survival. GM-CSF induces proliferation, is involved in hematopoietic differentiation of dendritic cells and is a key factor in differentiation pathways leading from stem cells. GM-CSF activates effector functions of myeloid cells, thereby linking adaptive and innate immunity and in turn may boost anti-tumor immunity (4). GM-CSF receptor is composed of GM-CSFRα and the common β chain, βC, which is also utilized by IL-3 and IL-5 (1). Binding of GM-CSF initiates the Jak2, Stat5 and PI3K/Akt pathways (1).


1.  Guthridge, M.A. et al. (1998) Stem Cells 16, 301-13.

2.  Sonoda, Y. et al. (1988) Proc Natl Acad Sci USA 85, 4360-4.

3.  Sonoda, Y. et al. (1988) Blood 72, 1381-6.

4.  de la Cruz-Merino, L. et al. (2008) Oncologist 13, 1246-54.

5.  Zhang, A.L. et al. (2007) Blood 110, 2484-93.


Entrez-Gene Id 1437
Swiss-Prot Acc. P04141


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.